An experimental theater program improved the emotional well-being of people with Parkinson’s disease, and eased their anxiety and depression, a study reports. “Arts-based interventions could offer a novel, efficient, and inexpensive tool to complement pharmacological therapy,” the study’s researchers wrote. The program outperformed an at-home memory and attention program at…
News
A low-cost, self-powered pen with magnetic ink may help detect early signs of Parkinson’s disease by analyzing handwriting. When the pen was tested, it was able to distinguish Parkinson’s patients from healthy people with an average accuracy of 96%, a study reports. “Detection of subtle motor symptoms unnoticeable to…
The U.S. Food and Drug Administration has approved Exablate Neuro, Insightec’s platform for noninvasive, MRI-guided focused ultrasound therapy, for the bilateral treatment of motor symptoms in patients with advanced Parkinson’s disease who no longer respond to medication. The therapy targets regions within the pallidothalamic tract, a brain pathway…
Ambroxol, a common cough medicine, may help stabilize neuropsychiatric symptoms in Parkinson’s disease dementia (PDD) and shows cognitive promise for patients with mutations in the GBA1 gene, according to results from a Phase 2 clinical trial. While ambroxol is widely used in Europe to treat respiratory conditions, it’s not approved…
Genetic analysis of saliva may offer a noninvasive way to assess the risk of developing Parkinson’s disease, according to a saliva-based DNA study led by researchers at the University of the Basque Country (EHU) in Spain. The scientists found that molecular markers in saliva can reflect whole-body disease processes,…
Note: This story was updated Oct. 7, 2025, to correct the headline and first paragraph to reflect that while Pharmather is developing ketamine to ease Parkinson’s symptoms, the company was awaiting an FDA decision on a ketamine therapy for surgical pain management. Pharmather is advancing its ketamine-based treatment for…
Target enrollment for a Phase 1b clinical study assessing the safety and tolerability of GT-02287 in people with Parkinson’s disease is complete, three months ahead of the original goal, the therapy’s developer said. After enrolling the first 16 participants, the Phase 1b clinical trial (NCT06732180) is recruiting up…
People in the prodromal, or presymptomatic, stage of Parkinson’s disease show increased immune activity, with T cells targeting the proteins PINK1 and alpha-synuclein at levels similar to those seen in patients already diagnosed with the neurodegenerative condition, a new study reports. These two proteins — PINK1 and alpha-synuclein —…
BioVie’s ongoing SUNRISE-PD clinical trial of bezisterim in early Parkinson’s disease uses a hybrid, decentralized approach to center patient experience and promote accessibility, according to the company. Parkinson’s disease patients often face barriers to accessing specialized care and participating in clinical trials due to delayed diagnosis, limited mobility, and…
A trio of prominent Parkinson’s disease advocacy groups are calling on the U.S. federal government to provide strong funding and support for the National Institutes of Health (NIH) — a federal agency that is a major driver of biomedical research around the world. The American Parkinson Disease Association,…
Recent Posts
- Parkinson’s therapy reduces disease biomarkers in 12-week trial
- Ozone air pollution exposure may increase Parkinson’s risk: Study
- When standing still meant something different for Uncle Brandon
- Fecal transplants offer brief relief from Parkinson’s motor symptoms
- Turmeric compound may protect motor function in Parkinson’s mouse model